Provided by Tiger Trade Technology Pte. Ltd.

MannKind

3.95
+0.05001.28%
Post-market: 3.90-0.0500-1.27%19:30 EDT
Volume:10.19M
Turnover:40.82M
Market Cap:1.27B
PE:-28.21
High:4.23
Open:3.84
Low:3.83
Close:3.90
52wk High:6.51
52wk Low:2.23
Shares:321.54M
Float Shares:309.97M
Volume Ratio:1.63
T/O Rate:3.29%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.1400
EPS(LYR):0.0200
ROE:32.74%
ROA:0.79%
PB:-18.90
PE(LYR):197.50

Loading ...

MannKind's Furoscix ReadyFlow Injection Approved by US FDA

MT Newswires Live
·
Jul 24

Mannkind Corp Shares up 5.4% Premarket After FDA Approves Co's Single-use Autoinjector to Treat Fluid Buildup

THOMSON REUTERS
·
Jul 24

Mannkind Prices USD 50 Million Private Placement at USD 3.89 Per Share

Reuters
·
Jul 24

Mannkind Announces $50 Million Private Placement

THOMSON REUTERS
·
Jul 24

MannKind Announces $50 Million Private Placement

GlobeNewswire
·
Jul 24

Mannkind Corp - Furoscix Readyflow Expected to be Available in U.S. by End of August 2026

THOMSON REUTERS
·
Jul 24

Mannkind Announces FDA Approval of Furoscix Readyflow™, the First and Only Autoinjector Delivering Iv-equivalent Diuretic Therapy for the Treatment of Edema in Adults with Heart Failure or Chronic Kidney Disease

THOMSON REUTERS
·
Jul 24

MannKind nearing ‘underappreciated catalyst,’ says H.C. Wainwright

TIPRANKS
·
Jul 23

MannKind (MNKD) Stock Stays Cheap On Its 28% YTD Slump

Simply Wall St.
·
Jul 19

Mannkind Director Steven B. Binder Disposes of USD 214,089 Common Shares

Reuters
·
Jul 18

MannKind (MNKD) Secures Pediatric Afrezza Grant, Is The Stock Still Cheap?

Simply Wall St.
·
Jun 26

MannKind Awarded Breakthrough T1d Grant to Support Advancement of Inhale-1St Pediatric Trial of Afrezza® in Youth With Newly-Diagnosed T1d

THOMSON REUTERS
·
Jun 23

MannKind wins Breakthrough T1D grant for INHALE-1ST pediatric Afrezza trial

Reuters
·
Jun 23

Should Afrezza Pediatric Approval And New Data Shift MannKind’s (MNKD) Technosphere Platform Investment Narrative?

Simply Wall St.
·
Jun 09

Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind’s Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) Systems

GlobeNewswire
·
Jun 06

MannKind Completes Patient Randomization in Phase 1b Idiopathic Pulmonary Fibrosis Study

MT Newswires Live
·
Jun 03

MannKind announces milestones in development of nintedanib DPI for IPF

TIPRANKS
·
Jun 03

MannKind enrolls first patient in Phase 2 INFLO-2 trial of inhaled nintedanib for IPF

Reuters
·
Jun 03

MannKind Enters Data-Rich Development Period With Completion of Randomization in Phase 1B Inflo-1 Study and Enrollment of First Patient in Phase 2 Inflo-2 Trial for Nintedanib DPI in Patients With Ipf

THOMSON REUTERS
·
Jun 03

MannKind - Expects Phase 1B Inflo-1 Data Readout in Q3 2026

THOMSON REUTERS
·
Jun 03